Phase 2 trial shows significant reduction in drinks per drinking day and weekly alcohol craving
Overall, retirement associated with higher levels of depression
Increases of 2.5-fold seen for women, 2.4-fold for Asians and Pacific Islanders, 2.5-fold in the Midwest
Semaglutide and liraglutide also linked to reduction in risks for SUD hospitalization, somatic hospitalizations
Greatest relative increases in AILD-related hospitalizations, liver transplants seen in younger individuals, especially women
Additional benefits include significant improvement in the physical and mental states of people with alcohol use disorder
Prescription of GIP/GLP-1 RA linked to lower rates of opioid overdose and alcohol intoxication
Higher binge-drinking prevalence reported by race, ethnicity-defined subgroups
Patients treated with antidepressants whose symptoms do not improve show more relapses in alcohol use disorder
Findings show risk cut in half based on electronic health record data